Does Blue Cross Blue Shield of Michigan Cover Dupixent?

How BCBSM Classifies Dupixent on Its Formulary

Blue Cross Blue Shield of Michigan places Dupixent (dupilumab) on its specialty pharmacy tier across most commercial PPO, HMO, and Medicare Advantage plans. That classification means the drug is covered but subject to higher cost-sharing and additional utilization management controls compared to standard formulary medications.

BCBSM's pharmacy benefit management unit evaluates biologic therapies using clinical criteria drawn from FDA labeling and peer-reviewed evidence. Dupixent earned FDA approval for moderate-to-severe atopic dermatitis in adults in March 2017 and has since accumulated six distinct indications 1. The plan's clinical policy bulletins reference the same key trial data the FDA reviewed. For atopic dermatitis specifically, BCBSM's criteria align with findings from the LIBERTY AD SOLO 1 and SOLO 2 trials (combined N=1,379), which demonstrated that dupilumab 300 mg every two weeks achieved an IGA score of 0 or 1 in 38% of patients at week 16, compared with 10% receiving placebo 2.

Coverage extends to both self-funded employer groups that use BCBSM's network and fully insured individual and family plans sold on the Health Insurance Marketplace in Michigan. Self-funded groups may customize their formulary, so a small number of employer plans could exclude dupilumab or impose different step-therapy sequences. Members should verify their specific plan document or call the number on the back of their insurance card.

Prior Authorization Requirements

Every BCBSM member prescribed Dupixent must obtain prior authorization before the specialty pharmacy will dispense the medication. No exceptions exist for any indication. The prescribing clinician submits the request.

The prior authorization form requires documentation of the patient's diagnosis, disease severity score (such as EASI or IGA for atopic dermatitis), prior treatments attempted, and confirmation that the patient meets age requirements for the specific indication. For moderate-to-severe atopic dermatitis in adults, BCBSM typically requires evidence that the patient has tried and failed, or is intolerant of, at least one topical therapy such as a medium-to-high-potency topical corticosteroid or a topical calcineurin inhibitor 3. The American Academy of Dermatology (AAD) guidelines support this sequencing, recommending that systemic therapies be considered after inadequate response to optimized topical regimens 4.

BCBSM processes most prior authorization requests within 72 hours for standard reviews and within 24 hours for urgent clinical situations. If the prescriber marks the request as urgent (for example, a patient experiencing severe flare requiring rapid escalation), the plan is required by Michigan insurance regulations to respond within one business day.

Initial authorization periods typically last 6 to 12 months. Renewal requests require documentation of clinical response, such as a 50% or greater improvement in EASI score or sustained IGA of 0 or 1.

Step Therapy Criteria by Indication

BCBSM applies indication-specific step therapy protocols. The required prior treatments vary depending on which condition the prescriber is treating.

For atopic dermatitis, the plan requires failure of at least one topical corticosteroid (medium potency or higher) or topical calcineurin inhibitor. Some plan documents also require a trial of a systemic immunosuppressant such as methotrexate or cyclosporine before approving dupilumab, though this requirement has become less common since the 2023 AAD guideline update, which positioned dupilumab as a first-line systemic option 4.

For moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma, BCBSM generally requires that the patient is already on a medium-to-high-dose inhaled corticosteroid plus a second controller (such as a long-acting beta-agonist). The LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab reduced annualized severe exacerbation rates by 47.7% in patients with baseline eosinophils of 150 cells/µL or higher 5.

For chronic rhinosinusitis with nasal polyps (CRSwNP), step therapy requires prior use of intranasal corticosteroids and at least one course of systemic corticosteroids or a prior sinus surgery. The LIBERTY NP SINUS-24 trial (N=276) demonstrated a 2.06-point improvement in nasal polyp score versus placebo at week 24 6.

For eosinophilic esophagitis (EoE), the plan requires documented failure of proton pump inhibitor therapy. For prurigo nodularis, prior topical therapy failure must be documented. For COPD with type 2 inflammation, the patient must have evidence of elevated eosinophils and be on maximized inhaled therapy.

What Dupixent Costs with BCBSM Coverage

Out-of-pocket costs depend entirely on your plan design. That single variable creates a wide range of possible expenses for the same drug.

Dupixent's wholesale acquisition cost sits at approximately $3,700 per 300 mg prefilled syringe, translating to roughly $44,000 to $48,000 per year for patients on the standard every-two-week dosing schedule 7. BCBSM commercial PPO members on a standard specialty tier typically pay a coinsurance rate of 20% to 30% after meeting their deductible, though annual out-of-pocket maximums cap total yearly spending. For a member with a $2,000 deductible and 25% coinsurance, the first few months of the year could cost $925 per fill until the out-of-pocket maximum (often $4,000 to $8,700 for individual coverage) is reached.

BCBSM Medicare Advantage plans follow a different structure. Dupixent falls under Medicare Part D specialty tier (Tier 5), where coinsurance is typically 25% to 33% during the initial coverage phase. The Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap, which took full effect in 2025, provides meaningful protection for Medicare enrollees using high-cost biologics 8.

Members enrolled in BCBSM's Blue Care Network (BCN) HMO products face similar specialty tier coinsurance but may have different out-of-pocket maximum thresholds. BCN plans also require that the prescribing physician be within the HMO network for the prior authorization to proceed.

The Dupixent MyWay Copay Assistance Program

Sanofi and Regeneron operate the Dupixent MyWay program, which can reduce out-of-pocket costs for eligible commercially insured patients to as little as $0 per month. This program is not available to patients covered by government insurance (Medicare, Medicaid, Tricare, or VA).

The copay card covers up to $13,000 per calendar year in out-of-pocket costs. For most BCBSM commercial members, this amount exceeds what they would owe annually, effectively eliminating copays for the duration of their treatment. Enrollment requires a valid prescription and proof of commercial insurance coverage. The program does not count copay card payments toward the member's deductible or out-of-pocket maximum, a distinction that matters for patients also managing costs for other specialty medications.

"The manufacturer copay assistance programs for biologics like dupilumab have become a critical access tool," noted Dr. Jonathan Silverberg, Professor of Dermatology at George Washington University School of Medicine. "Without them, even insured patients face significant financial barriers to biologic therapy" 9.

For patients who are uninsured or whose insurance does not cover Dupixent at all, separate patient assistance programs through Sanofi Genzyme may provide the drug at no cost based on income eligibility.

How to Manage a Prior Authorization Denial

BCBSM denies prior authorization requests when submitted documentation does not meet the plan's clinical criteria. A denial does not mean permanent exclusion from coverage. It means the current submission was insufficient.

The most common reasons for denial include: incomplete documentation of prior therapy failure, missing disease severity scores, prescriber not specifying the correct FDA-approved indication, or the patient not meeting age criteria for a particular indication (dupilumab is approved for atopic dermatitis in patients aged 6 months and older, but some plan criteria lag behind the most recent FDA label expansion) 10.

When a denial occurs, members have the right to a two-level internal appeal process under Michigan insurance law. The first-level appeal must be filed within 60 days of the denial notice. The prescribing physician should submit a letter of medical necessity that directly addresses the specific denial reason, includes updated clinical documentation, and cites relevant clinical trial evidence or guideline recommendations.

"A well-documented appeal that directly references the specific coverage criteria the plan uses is far more likely to succeed than a generic letter of medical necessity," stated Dr. Amy Paller, Chair of Dermatology at Northwestern University Feinberg School of Medicine 11.

If the first appeal is denied, members can request an external independent review through the Michigan Department of Insurance and Financial Services (DIFS). The external reviewer's decision is binding on BCBSM.

Specialty Pharmacy Dispensing and Delivery

BCBSM routes most Dupixent prescriptions through its preferred specialty pharmacy network. For fully insured commercial members, the designated specialty pharmacy is typically AllianceRx Walgreens Prime, though some plan configurations use Optum Specialty Pharmacy or Accredo.

Specialty pharmacies provide services beyond standard dispensing. These include cold-chain shipping (dupilumab requires refrigeration at 2°C to 8°C), injection training for patients self-administering at home, refill coordination timed to the every-two-week dosing schedule, and clinical pharmacist check-ins to monitor for side effects. The most commonly reported adverse reactions in clinical trials were injection site reactions (occurring in 15% of dupilumab-treated patients versus 7% on placebo in SOLO 1 and SOLO 2) and conjunctivitis (10% versus 2%) 2.

Members cannot fill Dupixent prescriptions at retail pharmacies. Attempting to do so will result in a claim rejection. The prescriber must send the prescription directly to the specialty pharmacy, which then coordinates the prior authorization and benefit verification before the first shipment.

Home delivery is standard. Most patients receive a 30-day supply (two prefilled syringes or pens for biweekly dosing) shipped in temperature-controlled packaging. Deliveries typically arrive within 1 to 3 business days of the scheduled refill date.

Coverage Differences Across BCBSM Plan Types

Not all BCBSM plans are identical. The plan type determines formulary details, cost-sharing, and network requirements.

BCBSM offers several distinct product lines in Michigan: commercial PPO, Blue Care Network (BCN) HMO, Medicare Advantage PPO, Medicare Advantage HMO, Medicaid managed care, and Federal Employee Program (FEP) plans. Each product line maintains its own formulary committee and clinical policy set.

Commercial PPO plans generally offer the broadest access, with dupilumab covered under the specialty pharmacy benefit. BCN HMO plans also cover it but require in-network prescribers and may have slightly different step-therapy sequences. Medicare Advantage plans follow CMS coverage determination guidance, which recognizes dupilumab for all six FDA-approved indications. FEP plans follow the FEP formulary managed nationally by the Blue Cross Blue Shield Association, where dupilumab sits on the specialty tier with prior authorization required.

For Medicaid managed care through BCBSM (serving Healthy Michigan Plan enrollees), dupilumab access follows the Michigan Department of Health and Human Services (MDHHS) preferred drug list. Medicaid members generally have lower out-of-pocket costs (copays of $1 to $3 per prescription) but may face more restrictive step-therapy requirements, including documented failure of systemic immunosuppressants before biologic approval.

Members switching between BCBSM plan types (for example, moving from employer-sponsored commercial coverage to Medicare Advantage at age 65) should request a new prior authorization under the new plan, as approvals do not transfer between product lines.

Comparing Dupixent Coverage to Alternative Biologics

BCBSM covers several biologic and targeted therapies that compete with Dupixent across its indications. Understanding relative coverage positioning helps patients and prescribers anticipate potential step-therapy sequences.

For atopic dermatitis, alternatives covered by BCBSM include JAK inhibitors such as abrocitinib (Cibinqo) and upadacitinib (Rinvoq), as well as the IL-13 inhibitor tralokinumab (Adbry). BCBSM's formulary positions dupilumab and these alternatives similarly, with no preferential biologic. The choice typically comes down to clinical factors. The HEADS UP trial (N=692), a head-to-head comparison, showed upadacitinib 30 mg achieved EASI-75 in 71% of patients versus 61% for dupilumab at week 16, though dupilumab had a more favorable safety profile with fewer serious adverse events 12.

For asthma, alternative biologics on the BCBSM formulary include omalizumab (Xolair), mepolizumab (Nucala), benralizumab (Fasenra), and tezepelumab (Tezspire). Each targets a different pathway, and BCBSM does not impose a specific biologic sequence. The prescriber selects based on biomarker profile (IgE levels, eosinophil count, FeNO).

For CRSwNP, omalizumab and mepolizumab are also covered options. The SYNAPSE trial (N=407) demonstrated mepolizumab reduced nasal polyp score by 0.73 points versus placebo, a smaller effect size than dupilumab's 2.06-point reduction in SINUS-24, though direct cross-trial comparisons carry methodological limitations 13.

All competing biologics on the BCBSM formulary require prior authorization and step therapy, so there is no shortcut to avoiding utilization management by switching agents.